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Dulaglutide is a,new once-weekly glucagon-like peptide-1 receptor agonist for the 
management of hyperglycemia in adult patients with type 2 diabetes. It stimulates dose-
dependent insulin secretion and reduces glucagon secretion, both in a glucose-dependent 
manner. Efficacy on blood glucose control and safety were demonstrated in the large 
AWARD program in type 2 diabetic patients treated with diet, metformin, dual oral therapy or 
insulin lispro with or without metformin, confirming findings of pilot studies in Caucasian 
patients and data in Japanese patients. Dulaglutide 1.5 mg once weekly was superior to 
metformin, sitagliptin, insulin glargine and exenatide twice daily, and non-inferior to 
liraglutide 1.8 mg once daily regarding the reduction in glycated hemoglobin. A modest but 
significant weight loss was consistently observed. Most frequent adverse events were 
transient and generally mild gastrointestinal disturbances. Clinical outcomes of dulaglutide 
will not be known until the large prospective cardiovascular outcome trial REWIND is 
complete.   
Key-words : Dulaglutide  – Clinical trial – GLP-1 receptor agonist – Insulin secretion – Once 




























Type 2 diabetes mellitus (T2DM) is increasingly prevalent worldwide and is linked to 
abdominal obesity in genetically predisposed individuals. [1] It is associated with a major 
burden for patients and society, mainly due to severe vascular complications that impair 
quality of life, reduce life expectancy and dramatically increase cost. [2] To prevent these 
complications, besides a global approach targeting all risk factors, guidelines for treating 
hyperglycemia recommend a patient-centered approach with metformin and lifestyle 
modifications as first-line therapy for most individuals.  [2-4] Second-line agents are diverse 
and increasingly numerous. [3] Currently, in most countries, the clinician has the choice 
between sulfonylureas, thiazolidinediones, dipeptidyl peptidase-4 (DPP-4) inhibitors 
(gliptins), [5] sodium-glucose cotransporter type 2 (SGLT2) inhibitors (gliflozins), [6] 
glucagon-like peptide-1 receptor agonists (GLP-1 RAs), [7] and insulin. [3] Because 
combined therapy is needed in many patients with T2DM, various fixed dose combinations 
are also available, mainly but not exclusively including metformin. Drug properties, as well as 
patient-specific characteristics and preferences, should be considered during the selection of 
second-line agents and a similar approach may be used when considering moving towards 
triple therapy. [3] Effect on body weight and avoidance of hypoglycemia were identified 
among the most important factors driving patient preferences regarding pharmacological 
therapy of T2DM. [8] In this respect, the development of the GLP-1 RAs represents a 
substantial advancement in the treatment of T2DM, especially because these agents can 
improve glucose control, with a low risk of hypoglycemia, while promoting weight loss. [1, 7, 
9, 10] GLP-1, an incretin hormone, stimulates insulin secretion and suppresses glucagon 
secretion in a glucose-dependent manner while delaying gastric emptying and promoting 
satiety. [7] Whereas native GLP-1 is rapidly inactivated by the enzyme DPP-4, GLP-1 RAs 
are modified to resist inactivation by DPP-4.  [7] Not all GLP-1 RAs are equal, with each 
having its own distinct pharmacokinetic and pharmacodynamic characteristics based on its 
molecular size. Schematically, they have been classified as short-acting and long-acting GLP-
1 RAs. [7] From a clinical point of view, the most obvious difference is that some GLP-1 RAs 
should be injected every day (exenatide immediate-release, liraglutide, lixisenatide) whereas 
others can be injected only once weekly (exenatide extended-release, albiglutide, dulaglutide, 


























daily injection may provide greater convenience, better medication adherence and improved 
quality of life. [11] 
Dulaglutide (LY2189265, Trulicity®) is a new long-acting human GLP-1 RA to be 
administered subcutaneously once weekly with the use of a pen device.  [12-15] The objective 
of this review article is to summarize the pharmacology, pharmacokinetics, 
pharmacodynamics, clinical efficacy and safety of dulaglutide, including very recent data in a 
rapidly evolving field, and to put into perspective this compound in comparison with other  
GLP-1 RAs and glucose-lowering agents for the management of T2DM. 
 
 
2. Structure of dulaglutide 
Dulaglutide is a GLP-1 immunoglobulin G (IgG4) Fc fusion protein with extended 
pharmacokinetics and activity. [16] Dulaglutide molecule consists of two identical, disulfide-
linked chains, each containing a human GLP-1 analog sequence covalently linked to a 
modified human immunoglobulin G4 (IgG4) heavy chain fragment (Fc) by a small peptide 
linker (Figure 1). The GLP-1 analog portion of dulaglutide is approximately 90% homologous 
to native human GLP-1. Some few amino acid substitutions aim at optimizing its clinical 
profile, including improved solubility of the peptide, protection from dipeptidyl peptidase-4 
(DPP-4) inactivation and reduced immunogenicity. The IgG-Fc increases the size of the 
molecule, thereby reducing the rate of clearance and drastically limiting its potential renal 
excretion. The IgG4 Fc portion of the molecule was also modified to prevent antibody 
formation and to reduce the potential for interaction with high affinity Fc receptors that may 
result in immunologic cytotoxicity. [17] 
 
3. Pharmacokinetics of dulaglutide  
 
3.1 Healthy subjects and patients with T2DM 
Following a single 1.5 mg subcutaneous dose administration in healthy volunteers, the 
absolute bioavailability of dulaglutide was found to be approximately 44%, probably due to 
metabolism/degradation at the site of injection. [17] In healthy subjects, the half-life of 
dulaglutide was approximately 90 h, with plasma maximum concentration (Cmax) occurring 


























A 5-week study evaluated the pharmacokinetics of dulaglutide in patients with T2DM. 
[19] The time to maximal plasma drug concentration (tmax) ranged from 12 to 72 hours and 
was similar between the first and the fifth dose. Assessment of trough dulaglutide 
concentrations indicated that steady-state plasma levels were obtained after the second weekly 
dose with an average accumulation ratio [area under the curve of plasma concentrations 
(AUC) at week 5 divided by the AUC at week 1] estimated to be 1.44. The average peak-to-
trough concentration ratio (Cmax : Cmin) was between two and three. The mean plasma half-life 
determined after the last dose was 95.4 h (approximately 4 days). The mean steady-state 
apparent clearance and volume of distribution were 0.157 l/h and 21.5 l, respectively. The 
intra-subject variability for Cmax and AUC(0 – 168 h) were 29.4 and 14.6%, respectively; 
corresponding values for intersubject variability were 28.5 and 30.8%, respectively. [19] 
Overall, these results were confirmed in pharmacokinetic meta-analysis of Phase 1 data 
and population pharmacokinetic modeling of Phase 2 and Phase 3 studies. [20] The 
pharmacokinetics of dulaglutide was well described by a 2-compartment model with first-
order absorption. After subcutaneous injection, dulaglutide was slowly absorbed and tmax at 
steady state ranged from 24 to 72 hours (median = 48 hours). The absolute bioavailability was 
47% and the half-life was estimated at 4.7 days. Steady state was achieved between 2 and 4 
weeks of dosing and the accumulation ratio was approximately 1.56. Mean volume of 
distribution after intravenous administration was 5.32 L, suggesting dulaglutide distributes 
primarily in the blood volume. Apparent clearance in patients with T2DM after multiple 1.5 
mg dosing was 0.107 L/hr. Body weight influenced dulaglutide pharmacokinetics, although 
weight explained < 6% of the inter-patient variability. Effects of age, body weight, sex, race 
and ethnicity on dulaglutide pharmacokinetics were not clinically relevant. Furthermore, 
injection site (abdomen, upper arm, thigh) had no statistically significant effect on exposure. 
Thus, the PK of dulaglutide 1.5 mg, especially its long half-life, supports once weekly 
administration in patients with T2DM and no dose adjustment is needed based on body 
weight, sex, age, race or ethnicity, or injection site. [17] 
 
3.2 Subjects with renal insufficiency 
Dulaglutide pharmacokinetics (after a single 1.5 mg subcutaneous dose) was examined 
in subjects with mildly impaired (estimated creatinine clearance or CrCL: 50-80 mL/min; 
n=8), moderately impaired (CrCL: 30-50mL/min; n=8), severely impaired renal function 


























group (n=16) with normal renal function. No relationship was observed between the main 
pharmacokinetic parameters (Cmax and total exposure reflected by AUC) and renal function 
based on estimated glomerular filtration rate. Overall, the results suggest that kidneys play a 
less important role in the elimination of dulaglutide, which is not unexpected given the large 
size of the protein. Consequently, dose adjustment in patients with mild to moderate renal 
impairment is not necessary. [17, 21] 
 
3.3 Subjects with hepatic impairment 
Dulaglutide pharmacokinetic parameters (again after a single 1.5 mg subcutaneous 
dose) were compared between subjects with mild hepatic impairment (Child-Pugh A; n=6), 
moderate hepatic impairment (Child-Pugh B; n=6), severe hepatic impairment (Child-Pugh C, 
n=3), and a control group with normal hepatic function (n=11). No increase in the dulaglutide 
exposure was seen in patients with hepatic impairment. On the contrary, statistically 
significant decreases in exposure were observed in all three hepatic impairment groups 
compared to healthy controls. [17] 
 
3.4 Subjects exposed to drug-drug interactions 
The elimination of dulaglutide is expected to be through proteolytic degradation into 
its amino acid components. Dulaglutide is not anticipated to be eliminated intact in the urine 
or to be metabolized by the CYP enzymes. Therefore, pharmacokinetic interactions with 
drugs primarily eliminated by the kidneys or metabolized by liver CYP enzymes are unlikely. 
However, dulaglutide causes a delay in gastric emptying, which may alter the 
pharmacokinetics of orally co-administered drugs, a condition that may be clinically 
important for drugs with a narrow therapeutic index. [17]  
 
4. Pharmacodynamics of dulaglutide 
4.1 Effect on insulin secretion 
In vitro and in vivo studies on T2DM models demonstrated glucose-dependent insulin 
secretion stimulation. In healthy subjects, pharmacodynamic parameters (plasma glucose and 
insulin concentrations) were measured following a step-glucose intravenous infusion and as 
part of an oral glucose tolerance test (OGTT). [18] Following a stepped glucose infusion, 


























concentrations with time and the time-matched insulin to glucose ratio showed a rapid 
increase in a dose-dependent fashion. [18] Evidence of increase in glucose-dependent insulin 
secretion and suppression of serum glucose excursions were also observed during an OGTT at 
all doses compared to placebo (doses ranging from 0.1 to 12 mg). [18] In T2DM patients 
treated with diet or metformin, following standard test meals, dulaglutide produced 
statistically significant increases in plasma insulin and C-peptide AUC when normalized for 
glucose AUC. [19]  
Measures of B-cell function and insulin sensitivity were estimated using the HOMA 
(Homeostasis Model Assessment) approach in several studies having evaluated dulaglutide. 
In two pilot dose-response 12-week studies in T2DM patients on diet and exercise, significant 
dose-dependent increases in HOMA2-%B (evaluating B-cell insulin secretory capacity) were 
observed across the dulaglutide groups receiving 0.1, 0.5, 1.0 and 1.5 mg once weekly in 
Caucasian patients [22]  and receiving 0.5, 1.0 and 1.5 mg once weekly in Japanese patients. 
[23] In patients with T2DM treated with diet and exercise in the 26-week AWARD-3 trial, 
HOMA2-%B increased in all treatment arms, but changes with dulaglutide 1.5 mg and 
dulaglutide 0.75 mg were greater than with metformin (P < 0.001, both comparisons).  [24] 
HOMA2-%S (an index of insulin sensitivity) also increased in the three arms, with greater 
changes with metformin compared with dulaglutide. Results were similar for the index of 
insulin secretion at 52 weeks, whereas the difference in the insulin sensitivity index between 
dulaglutide 1.5 mg and metformin was no longer significant. [24] In AWARD-5 trial [25] 
comparing dulaglutide (0.75 and 1.5 mg once weekly) with placebo and sitagliptin in T2DM 
patients on metformin monotherapy, HOMA2-%B at 52 weeks increased numerically in all 
arms versus baseline, but the changes observed were significantly greater with both 
dulaglutide doses compared with sitagliptin 100 mg (P <0.001). In contrast, no differences 
were observed among arms with respect to insulin sensitivity of the peripheral tissues, 
estimated by HOMA2-%S. [25] Almost similar results were obtained in the EGO 16-week 
trial comparing dulaglutide with placebo in patients with T2DM already treated with two oral 
antidiabetic agents, with significant increases of HOMA2-%B and no significant increase in 
HOMA2-%S versus placebo. [26]  


























Dulaglutide can lower blood glucose by stimulating insulin secretion but also by 
decreasing glucagon secretion. In the AWARD-3 study in T2DM patients treated with diet 
and exercise, at 26 weeks, fasting glucagon decreased with dulaglutide 1.5 mg and dulaglutide 
0.75 mg and was unchanged in the metformin group (P < 0.001, both comparisons) while at 
52 weeks, similar glucagon decreases were observed in the three treatment arms. [24] In 
addition, decreases in postprandial glucagon AUC (0-3 hours post-meal) were observed 
following a standardized test meal in this study. After 26 and 52 weeks of treatment with 
dulaglutide 1.5 mg, least squares mean decreases in glucagon AUC from baseline were -5.91 
pmol.h/L and - 8.04 pmol.h/L, respectively. [17] No such reductions in plasma glucagon 
levels were observed with the active comparator metformin.  
4.3 Effect on gastric emptying 
The effect of dulaglutide (1.5 mg subcutaneously once weekly for 4 weeks) has been 
evaluated on gastric emptying using scintigraphy. [17] Repeat scintigraphy (following a 
radiolabeled breakfast) at the time of the expected dulaglutide tmax showed statistically 
significant delays in gastric emptying rate following each of four 1.5 mg dulaglutide doses 
compared to baseline. The greatest delay was observed after the first dose, with a trend to 
decrease from the second dose onwards. [17] 
4.4 Effect on fasting and postprandial glycemia 
Once-weekly administration of dulaglutide (0.05, 0.3, 1, 3, 5 or 8 mg) significantly 
reduced fasting plasma glucose, 2-h post-test meal postprandial glucose and AUC of plasma 
glucose concentrations after test meals at doses ≥ 1 mg in patients with T2DM treated with 
lifestyle measures with or without metformin. These effects were seen after the first dose and 
were sustained through the weekly dosing cycle for 5 weeks. [19] These data were confirmed 
in a 12-week dose-response trial performed where dose-dependent reductions in fasting, pre-
meal and post-meal plasma glucose were observed, with tested dulaglutide doses being 0.1, 
0.5, 1.0 or 1.5 mg. [22] Dulaglutide at a dose of 1.0 or 2.0 mg administered once weekly for 
16 weeks has been shown to have a robust effect on fasting plasma glucose as well as on 
glucose excursions after a meal test. [26] 
 


























The clinical efficacy of dulaglutide, i.e its glucose-lowering activity assessed by 
reductions in fasting and postprandial glucose plasma concentrations and HbA1c levels 
combined with the body weight reducing effect, of dulaglutide has been carefully investigated 
in patients with T2DM in the AWARD program (Table 1). Background therapy varied 
according to the trial with T2DM patients treated with diet and exercise only (dulaglutide as 
monotherapy) (AWARD-3), [24] with metformin alone (dulaglutide as add-on therapy, i.e. 
dual therapy) (AWARD-5 and AWARD-6),  [25]  [27] with metformin + glimepiride 
(AWARD-2) [28] or metformin + pioglitazone (AWARD-1) [29] (i.e. dulaglutide as triple 
therapy) or with insulin with or without metformin (AWARD-4). [30] Trials comparing 
dulaglutide with other active glucose-lowering agents were primarily designed as non-
inferiority trials. Patients recruited for AWARD trials were typically Caucasian T2DM 
patients with a mean age between 55 and 60 years, a mean duration of diabetes between 3 and 
13 years and a mean body mass index around 33 kg/m². [23, 25, 27-30] Other pilot trials of 
smaller size have been also performed in Caucasian T2DM patients on diet alone [22] or on 
two oral antidiabetic agents [26].  
It is important to also analyze the clinical efficacy of dulaglutide in the Asian 
population because of possible differences in the two major pathophysiological components 
(defective insulin secretion versus insulin resistance) of T2DM in Asian compared with 
Caucasian people [31]. A recent meta-analysis of clinical trials with GLP-1 analogues showed 
indeed a greater HbA1c reduction in Asian-dominant studies than in non-Asian-dominant 
studies [32].  Recently results of clinical trials with dulaglutide have been reported in 
Japanese patients with T2DM treated with diet alone [23, 33] or with sulfonylurea and/or 
metformin are also available (Table 2 and Table 3). [34, 35]  
5.1 T2DM inadequately controlled with diet and exercise  
In a 12-week, double-blind, placebo-controlled, dose-response trial, dose-dependent 
reductions in HbA1c, fasting plasma glucose and body weight were observed with dulaglutide 
(0.1, 0.5, 1.0 and 1.5 mg once weekly versus placebo) in T2DM patients treated with diet 
alone (Table 2). [22] Similar findings were reported in Japanese patients with diet-treated 
T2DM in a 12-week trial comparing dulaglutide (0.25, 0.50 and 0.75 mg once weekly) with 
placebo (Table 2). [23] In AWARD-3, dulaglutide (0.75 mg or 1.5 mg once weekly) was 


























of treatment or at least 1,500 mg/day depending upon tolerability) in a double-blind 52-week 
trial (primary endpoint at 26 weeks) in patients with T2DM treated with diet alone or a small 
dose of an oral antihyperglycemic medication (discontinued before the study). Dulaglutide 1.5 
and 0.75 mg were superior to metformin in reducing HbA1c level and greater percentages of 
patients reached HbA1c targets <7.0% and ≤6.5% with dulaglutide 1.5 and 0.75 mg compared 
with metformin (P < 0.05, all comparisons) (Table 1). [24] In a phase 3, randomized, double-
blind, placebo-controlled, open-label comparator (liraglutide) trial in Japanese patients with 
T2DM treated with diet alone, once weekly dulaglutide (0.75 mg) was superior to placebo and 
non-inferior to once daily liraglutide (0.9 mg, dose recommended in Japan) for reduction in 
HbA1c at 26 weeks (primary endpoint) (Table 2). [33] In another longer 52-week trial  in 
Japanese patients treated with diet or oral monotherapy (excluding glitazone), dulaglutide 
0.75 mg once weekly was associated with a greater reduction in HbA1c compared with 
liraglutide 0.9 mg once daily (mean difference : -0.20%; 95% CI -0.39 to -0.01; p=0.04) 
(Table 3). [35] 
All these data demonstrate that dulaglutide as monotherapy improves glycemic control in 
patients with early stage T2DM. Dulaglutide once weekly was superior to placebo and 
metformin and non-inferior (or even slightly superior in one Japanese trial) to liraglutide once 
daily. 
5.2. T2DM inadequately controlled with metformin alone 
AWARD-5 was an adaptive, seamless, double-blind study comparing dulaglutide with 
placebo at 26 weeks and sitagliptin up to 104 weeks in T2DM patients  not well controlled 
with metformin  monotherapy ≥ 1500 mg/day. [25, 36] The study also included a dose-finding 
portion. [37] A Bayesian algorithm allowed for an efficient exploration of a large number of 
doses and selected dulaglutide doses of 1.5 and 0.75 mg for further investigation in this trial. 
[37] The primary objective of AWARD-5 was to compare (for non-inferiority and then 
superiority) dulaglutide 1.5 mg versus sitagliptin in change from baseline in HbA1c at 52 
weeks. [25] Both 0.75 mg and 1.5 mg doses of dulaglutide were superior to sitagliptin 100 mg 
(p < 0.001, both comparisons) (Table 1). No events of severe hypoglycemia were reported 
with dulaglutide. Mean weight changes at 52 weeks were greater with dulaglutide 1.5 mg 
and dulaglutide 0.75 mg compared with sitagliptin (P < 0.001, both comparisons) (Table 1). 
These results were confirmed at the final endpoint of 104 weeks. [36] Indeed, changes in 


























mean ± standard error) for dulaglutide 1.5 mg, dulaglutide 0.75 mg and sitagliptin 100 mg, 
respectively (p < 0.001, both dulaglutide doses versus sitagliptin). Weight loss at 104 weeks 
was greater with dulaglutide 1.5 mg (p < 0.001) and similar with dulaglutide 0.75 mg versus 
sitagliptin (2.88 ± 0.25, 2.39 ± 0.26 and 1.75 ± 0.25 kg, respectively). [36] 
AWARD-6 is a head-to-head, open-label, phase 3, non-inferiority trial, which compared 
the efficacy and safety of once-weekly dulaglutide 1.5 mg with once-daily liraglutide 1.8 
mg in patients with uncontrolled T2DM despite metformin ≥1500 mg/day. [27] The primary 
outcome was non-inferiority (margin 0·4%) of dulaglutide compared with liraglutide for 
change in HbA1c at 26 weeks. Least-squares mean reduction in HbA1c was similar in the two 
treatment groups (Table 1), demonstrating the non-inferiority of dulaglutide 1.5 mg once 
weekly compared with liraglutide 1.8 mg once daily. The hypoglycemia rate was similarly 
low in the two treatment groups, and no severe hypoglycemia was reported. Weight reduction 
was significantly more pronounced with liraglutide than with dulaglutide (Table 1). [27]   
 
5.3 T2DM inadequately controlled with metformin plus sulfonylurea  
In a placebo-controlled, double-blind 16-week trial (EGO study) [26]
 
in T2DM patients 
not well controlled with two oral antidiabetic medications (metformin plus sulfonylurea in 
almost 75 % of patients), dulaglutide significantly and dose-dependently reduced HbA1c 
levels and fasting and postprandial glucose concentrations compared with placebo (Table 2). 
Hypoglycemia was uncommon overall (</=0.8 episodes/patient/30 days) but two- to threefold 
more common (especially during the initial 4 weeks, although not severe) with dulaglutide 
than placebo throughout the 16-week study period. A dose-dependent weight loss was also 
observed with dulaglutide after 16 weeks (Table 2). [26]  
AWARD-2 compared the efficacy and safety of two doses of dulaglutide once weekly 
with daily insulin glargine, both combined with maximally tolerated doses of metformin and 
glimepiride in patients with T2DM. [28] Concerning the HbA1c change from baseline at 52 
weeks (primary objective), statistical criteria for superiority were met with dulaglutide 1.5 mg 
and for noninferiority with dulaglutide 0.75 mg compared with glargine (Table 1). More 
patients on dulaglutide 1.5 mg achieved HbA1c targets <7.0% versus glargine (P < 0.001). 
However, in AWARD-2, glargine was used without forced titration (mean daily dose at 52 
weeks : 29 UI). Body weight decreased with dulaglutide and increased with glargine (Table 


























with almost no severe hypoglycemia. Similar findings were reported at the final endpoint of 
78 weeks. [28] 
The results of AWARD-2 were confirmed in another randomized, open-label, phase 3, 
non-inferiority study in Japanese patients with T2DM treated with sulfonylurea and/or 
biguanide (metformin). [34] At week 26, the reduction in HbA1c was significantly greater 
with dulaglutide 0.75 mg once weekly than with glargine (Table 2). However, the mean daily 
dose of glargine at endpoint was rather low (only 12.5 UI/day). Nevertheless, the incidence of 
hypoglycemia was significantly (P < 0.001) lower with dulaglutide (26%) than with glargine 
(48%). Furthermore, dulaglutide significantly reduced body weight compared with glargine at 
week 26 (Table 2). [34] 
5.4 T2DM inadequately controlled with metformin plus pioglitazone  
In AWARD-1 among T2DM patients treated with metformin (1,500-3,000 mg/day) and 
pioglitazone (30-45 mg/day), 0.75 and 1.5 mg dulaglutide doses once weekly were superior to 
placebo at 26 weeks  (primary endpoint) in reducing HbA1c (both P < 0.001) and also 
superior to exenatide 10 µg twice daily at 26 and 52 weeks (both P < 0.001) (Table 1). 
Greater percentages of patients reached HbA1c targets with dulaglutide 1.5 mg and 0.75 mg 
than with placebo and exenatide (all P < 0.001). [29] Weight loss was lower with dulaglutide 
0.75 mg and similar with dulaglutide 1.5 mg once weekly as compared with exenatide 10 µg 
twice daily (Table 1). 
5.5 T2DM inadequately controlled with prandial insulin  
AWARD-4 was a randomized, open-label, phase 3, non-inferiority study, which aimed to 
compare the efficacy and safety of dulaglutide with that of insulin glargine, both combined 
with prandial insulin lispro, in patients with T2DM (receiving or not metformin). [30] At 26 
weeks, the adjusted mean change in HbA1c was greater in patients receiving dulaglutide 1.5 
mg and dulaglutide 0.75 mg than in those receiving glargine (Table 1). The proportion of 
patients achieving an HbA1c target of less than 7∙0% was significantly greater in both the 
dulaglutide 1∙5 mg and 0·75 mg groups versus glargine whose dose was titrated up to a mean 
of 64 units/day (P=0.014 and P=0.010, respectively). Similar results were noticed at 52 
weeks. The reductions in the mean of all fasting and pre-meal plasma glucose concentrations 


























glucose values was significantly greater with dulaglutide 1.5 mg. However, it is noteworthy 
that the doses of preprandial lispro were less in the glargine group and in the two dulaglutide 
groups. Patients treated with dulaglutide 1.5 mg lost weight, those on dulaglutide 0.75 mg 
maintained their body weight and those on glargine gained weight after 26 and 52 weeks 
(Table 1). The rates of total and nocturnal hypoglycemia were significantly lower in the 1.5 
mg dulaglutide group than in the glargine group at both 26 and 52 weeks (P<0.001). [30] The 
conclusion was that dulaglutide in combination with lispro with or without metformin resulted 
in a significantly greater improvement in glycemic control than did glargine. Thus, it may 
represent a new treatment option for patients unable to achieve glycemic targets with insulin 
therapy. 
6. Tolerance and safety of dulaglutide 
Overall, the safety profile of dulaglutide in clinical trials was similar to that of 
currently available GLP-1 RAs, characterized predominantly by gastrointestinal symptoms.  
[12-15] Nausea, vomiting and diarrhea were all significantly more common in patients taking 
dulaglutide 1.5 and 0.75 mg compared with placebo, and slightly more frequent with the 
higher dose of dulaglutide compared with the lower dose. However, gastrointestinal adverse 
events were mostly mild to moderate and transient in nature. In the six landmark trials of the 
AWARD program, rates of nausea ranged from 15.4% to 28% and from 7.7% to 17.7% in the 
dulaglutide 1.5 mg and 0.75 mg groups, respectively. Vomiting was less common, occurring 
in 7% to 17% of patients in the dulaglutide 1.5 mg group and 5.9% to 10.6% in the 
dulaglutide 0.75 mg group. Diarrhea occurred in 10% to 16.6% and 5.2% to 15.7% of patients 
receiving dulaglutide 1.5 mg and 0.75 mg, respectively. No clear-cut differences in 
gastrointestinal complaints were observed between dulaglutide 1.5 mg and exenatide 
immediate-release (10 µg injected twice daily) in AWARD-1 [29] and liraglutide (1.8 mg 
once daily) in AWARD-6. [27] However, both exenatide and liraglutide required initial 
titration to minimize gastrointestinal side effects, which was not the case with dulaglutide.  
Dulaglutide as a GLP-1 RA stimulates insulin secretion and inhibits glucagon secretion 
in a glucose-dependent manner. [7] This explains the low risk of hypoglycemia, almost 
similar to that observed with placebo (AWARD-1 and AWARD-5), [25, 29] metformin 
(AWARD-3) [24] or sitagliptin (AWARD-5) [25]  and lower than that observed with insulin 
glargine (AWARD-2 and AWARD-4).  [28, 30] Overall, rates of hypoglycemia with 


























cause hypoglycemia, such as insulin and sulfonylureas (AWARD-2 and AWARD-4).  [28]  
[30] In those patients already on insulin or sulfonylurea, the risk of hypoglycemia when adding 
dulaglutide could be minimized by an initial reduction of the doses of insulin or 
sulfonylureas, especially if HbA1c level is not markedly elevated. Of major interest, there 
were no reports of severe hypoglycemia occurring in any trial of the AWARD program with 
dulaglutide. 
Injection-site reactions (hematoma, injection site reaction, erythema) in patients 
receiving dulaglutide were scarce in currently available clinical trials (1.7 % versus 0.9% with 
placebo),  [17] and apparently much less frequent as compared to exenatide extended release 
using the technique of microspheres. [38] As with other GLP-1 RAs, development of 
antibodies against the medication may potentially lead to reduced efficacy and/or changes in 
the safety profile. The risk with dulaglutide appears to be low in trials that measured 
antibodies, presumably because of the nature of the product (see above section 2. Structure of 
dulaglutide). Only one skin hypersensitivity reaction occurred among patients participating to 
the AWARD program. [22] 
Increases in pancreatic enzymes may be noticed among patients taking dulaglutide (1.5% 
versus 0.7% in all comparators).  [17] However, the cases of pancreatitis were rare in the 
AWARD program and in phase 2-3 clinical studies, although apparently more frequent in 
patients receiving dulaglutide compared with other glucose-lowering drugs (confirmed 
pancreatitis occurred in 5 patients taking dulaglutide and in 1 patient taking a nonincretin 
agent).  [14, 17] Therefore, the US Food and Drug Administration has required the inclusion 
of this risk in the Risk Evaluation and Mitigation Strategy program for dulaglutide, as it was 
already requested for other GLP-1 RAs. 
Overall, treatment of T2DM patients with dulaglutide in clinical trials did not alter 
kidney function or increase rates of adverse events related to kidney disease. [39] The 
cardiovascular safety of dulaglutide appears good, with no alarming signal noticed in the 
AWARD program, except a slight increase in heart rate. In AWARD trials, dulaglutide 1.5 
mg weekly compared with placebo was found to reduce systolic blood pressure (least squares 
mean = −2.8 mm Hg; P ≤ 0.001) and increase heart rate (least squares mean = +2.8 bpm; P < 
0.05). No significant differences were seen in blood pressure or heart rate when comparing 
dulaglutide with metformin, exenatide and liraglutide. After 52 weeks of therapy in AWARD-


























heart rate compared with sitagliptin 100 mg (+2.4, +2.1, −0.3 bpm, respectively; P < 0.001).  
[25] In a 16-week, randomized, double-blind, multicenter, placebo-controlled study 
specifically designed to investigate the hemodynamic changes induced by dulaglutide, [40] 
the dose of 1.5 mg once weekly was found to reduce systolic blood pressure (least squares 
mean = −2.8 mm Hg versus placebo; P ≤ 0.001) and increase heart rate (least squares mean = 
+2.8 bpm versus placebo; P < 0.05), thus confirming the findings of the placebo-controlled 
AWARD trials. The clinical significance of these minor changes is unknown. In a 
prespecified  meta-analysis of prospectively adjudicated cardiovascular events in 9 
randomized safety and efficacy trials (dulaglutide: n=3885; all comparators [active or 
placebo]: n=2125), treatment with dulaglutide was not associated with an increase in the risk 
of experiencing a composite of death due to cardiovascular causes, nonfatal myocardial 
infarction, nonfatal stroke, or hospitalization for unstable angina compared with control 
therapies (HR: 0.57; adjusted 98.02% CI: 0.30, 1.10)  [41]. The cardiovascular safety of 
dulaglutide will be further investigated in the ongoing cardiovascular outcome trial REWIND 
(Researching Cardiovascular Events With a Weekly Incretin in Diabetes) (see below section : 
Five year view). 
7. Drug formulation and dosing 
Dulaglutide is commercialized as a 0.75 mg/0.5 mL or 1.5 mg/0.5 mL solution in a 
prefilled automatic injection device. [17] The product does not require reconstitution, in 
contrast with exenatide extended-release. [38] The single-dose pen can be stored at room 
temperature for up to 14 days. The device is easy to be used : it extends a needle, delivers 
dulaglutide, and retracts the needle with the push of a button, so that patients have not to 
handle a needle. The dulaglutide single-dose pen was found to be a safe and effective device 
for use by patients with T2DM who were injection-naive. [42] 
Dulaglutide has to be injected subcutaneously once-weekly at any time of day, without 
regard to meals, into the abdomen, thigh, or upper arm. The initial starting dose is 0.75 mg 
once weekly, but the dose can be increased to 1.5 mg once weekly if additional glycemic 
control is needed. In Europe, the recommended dose is 0.75 mg once weekly as monotherapy 
and 1.5 mg once weekly as add-on therapy. However, for potentially vulnerable populations, 
such as patients ≥ 75 years, 0.75 mg once weekly can be considered as a starting dose. [21] 
Missed doses should be administered within 3 days or the patient has to wait for the next once 


























impairment. However, dulaglutide is not recommended in severe renal impairment (due to 
very limited experience in that group). [17, 21] 
 
8. Conclusion 
Dulaglutide is a new once-weekly GLP-1 RA approved by the US FDA and the EMA 
for the management of hyperglycemia in T2DM. Doses of 0.75 and 1.5 mg once-weekly have 
demonstrated HbA1c reduction of ∼0.7%–1.6% as monotherapy or in combination (dual or 
triple therapy) in controlled clinical trials. The glucose-lowering activity involves both 
reductions of fasting and postprandial plasma glucose concentrations, with a low risk of 
hypoglycemia. Compared with other GLP-1 RAs in the class, especially liraglutide once 
daily, it has been shown to be overall non-inferior for both safety and efficacy. It has been 
proven more effective than insulin glargine, however not uptitrated to target. As with other 
GLP-1 RAs, most common adverse events are transient gastrointestinal disturbances (nausea, 
diarrhea). Similar to other GLP-1 RAs, dulaglutide has demonstrated quite rapid and 
sustained weight loss of ∼1.5–3 kg, contrasting with a weight increase with insulin 
glargine.  In conclusion, dulaglutide is a novel option for treating T2DM that is easy for use, 
effective, well tolerated. It should be located alongside other long-acting GLP-1 RAs within 
the recommended guidelines. 
Expert commentary 
 Current guideline recommendations place GLP-1 RAs as second-line therapy behind 
first-line metformin, as third-line therapy after failure of dual oral therapy or even as add-on 
to insulin for a majority of patients with T2DM. [3]  [4] GLP-1 RAs lower both fasting and 
postprandial plasma glucose, but each formulation may differ in the extent to which it lowers 
the glucose level. [43] Available data from clinical trials with dulaglutide confirm that the 
compound lowers both fasting and postprandial glucose levels although the reduction in 
fasting plasma glucose concentrations appears to be more consistent than the decrease of 
postprandial glucose levels. [26]
 
Besides the glucose-lowering effect with no or only little 
increase of hypoglycemia, dulaglutide, as other GLP-1 RAs, offers the advantage of a 
significant reduction in body weight, an effect that could positively affect other weight-related 
risk factors  [9] and also possibly patient’s preference and quality of  life  [8]. However, long-


























and cost-effectiveness remain to be investigated in adequately powered, prospective, 
controlled clinical trials.  [44] 
Several once weekly GLP-1 RAs are currently available (exenatide extended-release, 
albiglutide, dulaglutide) and others are in late phase of development (semaglutide). [43] No 
clinical trial directly compared the efficacy and safety of these once weekly GLP-1 RAs but 
each of three compounds already commercialized has been compared in head-to-head trials 
with the once- daily GLP-1 RA liraglutide (at the maximum dose of 1.8 mg for treating 
T2DM) used as reference (Table 3) [45]. Although 2 mg exenatide extended-release [46] and 
30 mg albiglutide [47] failed to reach non-inferiority versus liraglutide 1.8 mg [26], 1.5 mg 
dulaglutide succeeded in AWARD-6, all studies being performed in metformin-treated T2DM 
patients [45]. Indeed, dulaglutide 1.5 mg once weekly proved to be non-inferior to liraglutide 
1.8 mg once daily regarding the reduction in HbA1c level although liraglutide was 
accompanied by a slightly but significantly greater weight loss compared with dulaglutide 
(Table 3) [26]. In Japanese patients, dulaglutide once weekly showed also similar or even 
better efficacy in reducing HbA1c compared with liraglutide once daily. [33, 35] From these 
respective comparisons with liraglutide 1.8 mg, one might hypothesize that dulaglutide 1.5 
mg is more potent than exenatide extended-release 2 mg or albiglutide 30 mg in improving 
hyperglycemia in T2DM patients treated with metformin [45]. However, caution is needed 
when analyzing such indirect comparative results and a head-to-head comparative trial 
between dulaglutide, albiglutide and exenatide extended-release would be necessary to draw 
definite conclusion. Nevertheless, one advantage of dulaglutide over some other GLP-1 RAs 
is that the drug is not eliminated via the kidneys and thus may be used without any dose 
adjustment in patients with mild to moderate renal impairment. [48] 
GLP-1 RAs are expensive agents for T2DM therapy. An important question that may 
arise in clinical practice is which patients will best benefit from a therapy with GLP-1 RA, in 
general, and dulaglutide, in particular? In United Kingdom, NICE (National Institute for 
Health and Care Excellence) recommends the use of GLP-1 RAs in patients with body mass 
index ≥ 35 kg/m² to profit of the weight reduction offered by this class of agents. [49] 
Nevertheless, HbA1c reduction obtained with GLP-1 RAs is generally similar in obese and 
non-obese patients. [7]  In France, the Haute Autorité de Santé (HAS) recommends the use of 
injectable agents such as GLP-1 RAs if HbA1c level is ≥ 1 % above the target with oral 
therapies because injectable medications have proven to be more efficacious to reduce HbA1c 


























higher cost). [50] Another possibility to optimize the therapeutic strategy is to detect as early 
as possible potential good responders to GLP-1 RAs.  Clinical markers of low β-cell function 
have been shown to be associated with reduced glycemic response to GLP-1 RA therapy both 
in a Caucasian population from UK [51] and in Asian patients, [52] with lower durability of 
the glucose-lowering effect as noticed with liraglutide therapy. [53] A post-hoc analysis of 
AWARD trials demonstrated that early (2 weeks) fasting glucose measurements can predict 
later glycemic response to once weekly dulaglutide. [54] 
Finally, it should be noticed that current available data don’t provide any information 
about the clinical efficacy of dulaglutide on hard outcomes, especially macrovascular and 
microvascular complications. Long-term (> 2 years) safety of dulaglutide remains largely 
unknown. We have to wait for the results of the ongoing long-term prospective outcome study 
(REWIND) to benefit from this important information from a clinical point of view (see next 
section Five-year view). 
 
Five-year view 
One may speculate that the place of GLP-1 RAs for the management of T2DM will 
continue to increase in the next few years. The current limitations are the higher cost, the 
necessity of subcutaneous injection and the gastrointestinal side effects. [3] The possibility to 
inject a GLP-1 RA once weekly instead of once daily would reduce the reluctance of patients 
to accept injections and possibly improve satisfaction and compliance, especially if efficacy is 
maintained and tolerance is improved. [11, 55] However, other modes of administration of 
GLP-1 RAs are currently in development. For instance, continuous subcutaneous delivery of 
exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in 
metformin-treated subjects with T2DM. [56] Whether such or other modes of administration 
may replace weekly injections of GLP-1 RAs in the future remains an open question. 
There are still questions remaining about long-term safety and efficacy of GLP-1 RAs. 
Regarding safety, the concern about a possible increased risk of acute pancreatitis and 
pancreatic cancer with incretin-based therapies seems less prominent now than a couple of 
years ago, even if post-marketing surveillance is still recommended. [57] The evaluation of 
this risk is part of the Risk Evaluation and Mitigation Strategy program for dulaglutide. 
Regarding clinical efficacy, no data are available yet demonstrating a positive effects of GLP-


























effects of GLP-1 RAs on major cardiovascular events are currently being investigated. [58]  
[59] As firm evidence that in T2DM cardiovascular disease can be reversed or prevented by 
improving glycemic control is still incomplete, [60] large, long-term clinical trials in patients 
using modern treatment strategies, i.e. drug combinations designed to maximize HbA1c 
reduction while minimizing hypoglycemia and excessive weight gain are of major interest. 
[61] The purpose of REWIND (ClinicalTrials.gov Identifier: NCT01394952) is to assess 
whether dulaglutide 1.5 mg once weekly can reduce major cardiovascular events and other 
serious outcomes in persons with T2DM, when added to their anti-hyperglycemic regimen. 
[62] The primary outcome measure is time from randomization to first occurrence of 
cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke (a composite 
cardiovascular outcome) and the estimated average duration of follow up is about 6.5 years. 
The estimated enrolment is about 9.600 T2DM patients with age ≥ 50 years with established 
clinical vascular disease, or age ≥ 55 years and subclinical vascular disease or age ≥ 60 years 
and at least two cardiovascular risk factors. Completion of the study is not expected before 
2019. It would be interesting at that time to compare the results of the different cardiovascular 
outcome trials performed with DPP-4 inhibitors, GLP-1 RAs or SGLT2 (sodium glucose 
cotransporters type 2) inhibitors. [58, 61] Such comparative analysis might help to guide the 
choice of the clinician in the future for the management of hyperglycemia in T2DM. [63] 
A review of dulaglutide at ClinicalTrials.gov reveals several ongoing trials, including 
studies comparing dulaglutide to placebo in patients already receiving sulfonylurea therapy 
(NCT01769378), glimepiride (NCT01644500), and once-daily basal glargine insulin 
(NCT01648582). The primary outcome for each of these studies is change in HbA1c at 24–26 
weeks. The future of GLP-1 RAs offers broader treatment options for T2DM as well as 
potential in other treatment areas. [64] Besides the combination with basal insulin in T2DM 
patients, [65, 66] GLP-1 RAs are currently being studied in new clinical areas, [64] as 
adjunctive therapy to insulin in patients with type 1 diabetes, [67] and for weight loss in obese 
non-diabetic individuals (especially liraglutide, which received recent approval as an anti-
obesity agent). [68] Up to now, dulaglutide has not been specifically investigated in these 
alternative indications other than the management of T2DM. Other exciting developments 
with GLP-1 RAs are ongoing with alternative modes of administration, either continuous 




























- Incretin-based therapies, including GLP-1 receptor agonists, occupy a growing 
place in the management of T2DM 
- Dulaglutide is a new human GLP-1 receptor agonist designed to be injected once 
weekly at a dose of 0.75-1.50 mg in Caucasian patients (lower doses in Japanese 
patients) 
- Dulaglutide reduces both fasting and postprandial glucose, mainly by stimulating 
insulin secretion and reducing glucagon secretion in a glucose-dependent manner, 
thus with a low risk of hypoglycemia 
- Dulaglutide has been evaluated in the AWARD program, mainly in Caucasian 
people, and the efficacy and safety results were confirmed in several trials 
performed in Japanese patients 
- Dulaglutide has proven its efficacy in reducing HbA1c in T2DM patients treated 
with diet alone, metformin, dual oral therapy (metformin plus sulfonylurea or 
metformin plus pioglitazone) and even lispro insulin 
- Dulaglutide 1.5 mg once weekly is more potent than metformin, exenatide, insulin 
glargine (if not forced titrated to target), and as effective as liraglutide 1.8 mg once 
daily 
- Dulaglutide has the same tolerance and safety profile as other GLP-1 RAs, with 
transient gastrointestinal disturbances as most frequent adverse events 
- Dulaglutide is currently evaluated in a large, prospective, cardiovascular outcome 
trial (REWIND) whose results are not awaited before 2019 
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Figure 1 : A) Schematic  structure of dulaglutide, a homodimer that consists of two identical 
polypeptide chains comprising a human glucagon-like peptide-1 (GLP-1) analog, a linker and 
a modified IgG4 Fc domain. B) Sequence of amino acids of dulaglutide (amino acids in 
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Placebo 141 8.1 (1.3) -0.46 (0.08)   94 (19) 1.24 (0.37)   
Giorgino et al 2014 






















































1.5 mg OW 
269 7.6 (0.9) -0.78 (0.06) 
-0.22 (-0.36 
to -0.08) 

















































=0.015 91.7 (18.0) 
+0.18 
(0.27) (*) 
NA < 0.0001 
Dulaglutide 
1.5 mg OW 











296 8.53 (1.03) 
-1.41 (0.07) 
(*) 








≥ 1500 mg 
Dulaglutide 





8.2 (1.1) -0.87 (0.06) 
-0.47 (NA) 
vs sitagliptin 









1.5 mg OW 
304 8.1 (1.1) -1.10 (0.06) 
-0.71 (NA) 
vs sitagliptin 














Placebo (**) 177 8.1 (1.1) 0.03 (0.07)   87 (17) NA   




≥ 1500 mg 
Dulaglutide 





























Δ : change versus baseline. SD : standard deviation. SE : standard error. OD : once-daily. OW : once-weekly. CI : confidence interval. NA : not 
available. NS : not significant. 
(*) SE not given in the paper and calculated from confidence intervals 
(**) Placebo arm limited to the first 26 weeks (results at 26 weeks only given for information) 



























Table 2 : Effects on HbA1c and body weight of dulaglutide in clinical trials outside the AWARD program in Caucasian and Japanese patients 



















































Caucasian T2DM patients 






0.5 mg OW 
34 
12 





<0.001 90.2 (21.3) -0.3 (0.4) NA NS 
Dulaglutide 







<0.001 86.9 (17.0) -1.1 (0.4) NA NS 
Dulaglutide 
1.5 mg OW 
29 7.3 (0.4) NA 
-1.04 (-1.39 
to -0.70) 
<0.001 85.8(18.6) -1.5 (0.5) NA NS (*) 
Placebo 32 7.4 (0.6) 0.01 (0.13)   90.9 (18.9) -1.4 (0.5) 
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Japanese T2DM patients 
Terauchi al 





0.25 mg OW 
36 
12 
8.1 (0.7) -0.90 (0.09) 
-0.72 (-0.95 
to -0.48) 
<0.01 74.0 (14.5) +0.4 (0.3) 




0.50 mg OW 
37 8.0 (0.7) -1.15 (0.09) 
-0.97 (-1.20 
to -0.73) 
<0.01 72.1 (12.8) -0.4 (0.3) 





























0.75 mg OW 
35 8.0  (0.6) -1.35 (0.09) 
-1.17 (-1.41 
to -0.93) 
<0.01 75.8 (10.8) -0.6(0.3) 
0.3 (-0.6 to 
1.1) 
NS 
Placebo 37 8.0 (0.6) -0.18 (0.09)   74.6 (13.6) -0.8 (03)   












8.15 (0.77) -1.43 (0.05) 
-1.57 (-1.79 
























Placebo 137 8.08 (0.89) 0.14 (0.10) 70.2 (12.5) -0.36 (NA) 
Liraglutide 







69.3 (11.6) -0.63 (NA) 





0.75 mg OW 
181 
26 
8.06 (0.82) -1.44 (0.05) 
-0.54  (-0.67 
to -0.41) 









Δ : change versus baseline. SD : standard deviation. SE : standard error. OD : once-daily. OW : once-weekly. CI : confidence interval. NA : not available. NS : not significant. 



























Table 3 : Effects on HbA1c and body weight in head-to-head trials of > 24 weeks duration comparing a once-weekly glucagon-like peptide-1 






















































Buse et al 2013 [46] 
(DURATION-6) 
Exenatide 
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1.8 mg OD 
450 26 8.4 (1.0)  -1.48 (0.05)  91.1 (19.1) 
-3.57 
(0.18) 
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-2.19 
(0.18) 
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1.8 mg OD 
300 26 8.1 (0.8) -1.36 (0.05) 94.4 (19.0) 
-3.61 
(0.22) 













0.9 mg OD 




Δ : change versus baseline. SD : standard deviation. SE : standard error. OD : once-daily. OW : once-weekly. CI : confidence interval. NA : not 
available. NS : not significant. 
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